Page 6 - உலகளாவிய மருத்துவ வாழ்க்கைத்தொழில்கள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Janssen Receives Two Positive CHMP Opinions Recommending Expanded Use of DARZALEX? (daratumumab) Subcutaneous (SC) Formulation for New Indications in Europe

Janssen Receives Two Positive CHMP Opinions Recommending Expanded Use of DARZALEX? (daratumumab) Subcutaneous (SC) Formulation for New Indications in Europe
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomCraig tendlerDaratumumab pomalidomideChristopher deloreficeVelcade melphalanBortezomib melphalanJennifer mcintyreNoah reymondVelcade bortezomib melphalanGlobal medical affairsJanssen biotech incAmerican society of hematology annual meetingAmerican society of clinical oncologyJanssen research developmentJanssen pharmaceutical companies

American Diabetes Association, with Visionary Partners VSP Vision Care and Regeneron Launch The Next Step Eye Challenge Campaign for Healthy Vision Month in May

American Diabetes Association, with Visionary Partners VSP Vision Care and Regeneron Launch The Next Step Eye Challenge Campaign for Healthy Vision Month in May News provided by Share this article Share this article ARLINGTON, Va., May 20, 2021 /PRNewswire/ Over 34 million American adults currently live with diabetes and an additional 88 million are living with prediabetes, yet 85% of them do not know they have it. People living with diabetes or prediabetes are at an increased risk for developing a diabetes-related eye disease, such as diabetic retinopathy, diabetic macular edema, glaucoma, and cataracts. Even more troubling, recent polls indicate that 1 in 4 people are putting off their annual eye exams due to the COVID-19 pandemic. Fortunately, vision loss from diabetes-related eye disease is 95% preventable with early detection, timely treatment, and appropriate follow-up care.

United statesKate renwick espinosaInstagram amdiabetesassnTraceyd brownDaisy diazJohnathan lancasterGlobal medical affairs at regeneronEyewear incFacebook american diabetes associationAmerican diabetes associationChief executive officerNext step eye challengeCare president kateVision monthSenior vice presidentGlobal medical affairs

IMBRUVICA® (ibrutinib)-Based Combination Regimen as a Fixed-Duration, First-Line Treatment for Chronic Lymphocytic Leukemia Demonstrates High Rates of Disease Control

Share this article Share this article RARITAN, N.J., May 19, 2021 /PRNewswire/ The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the fixed-duration cohort of the investigational Phase 2 CAPTIVATE study, showing that 95 percent of patients treated with combined IMBRUVICA ® plus venetoclax were alive and progression-free at two years. 1 Deep remissions were seen across all subgroups, including patients with high-risk chronic lymphocytic leukemia (CLL). 1 In addition, long-term data from the RESONATE-2 (PCYC-1115/1116) study will be presented, providing the longest follow-up Phase 3 data for any BTK inhibitor to date. These data reinforce the long-term survival benefits and well-established safety profile of single-agent IMBRUVICA

United statesCraig tendlerJennifer mcintyrePaolo ghiaChristopher deloreficeBernadette kingChristie corbettNone of the janssen pharmaceutical companiesGlobal medical affairsJanssen biotech incAmerican society of clinical oncologyDrug administrationJanssen research developmentJanssen pharmaceutical companiesJanssen pharmaceutical companies of johnsonExchange commission

Janssen: IMBRUVICA (ibrutinib)-Based Combination Regimen as a Fixed-Duration, First-Line Treatment for Chronic Lymphocytic Leukaemia Demonstrates High Rates of Disease Control

Janssen: IMBRUVICA (ibrutinib)-Based Combination Regimen as a Fixed-Duration, First-Line Treatment for Chronic Lymphocytic Leukaemia Demonstrates High Rates of Disease Control
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesCraig tendlerNoah reymondJennifer mcintyrePaolo ghiaChristopher deloreficeEdmond chanGlobal medical affairsJanssen biotech incAmerican society of clinical oncologyEuropean hematology associationJanssen research developmentJanssen pharmaceutical companiesJanssen pharmaceutical companies of johnsonAmerican society of hematologyAmerican society of clinical oncology annual meeting

IMBRUVICA® (ibrutinib)-Based Combination Regimen as a Fixed-Duration, First-Line Treatment for Chronic Lymphocytic Leukemia Demonstrates High Rates of Disease Control

IMBRUVICA® (ibrutinib)-Based Combination Regimen as a Fixed-Duration, First-Line Treatment for Chronic Lymphocytic Leukemia Demonstrates High Rates of Disease Control
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United statesCraig tendlerJennifer mcintyrePaolo ghiaChristopher deloreficeBernadette kingChristie corbettNone of the janssen pharmaceutical companiesGlobal medical affairsJanssen biotech incAmerican society of clinical oncologyDrug administrationJanssen research developmentJanssen pharmaceutical companiesJanssen pharmaceutical companies of johnsonExchange commission